Literature DB >> 4587143

Immunopotentiation with BCG. IV. Factors affecting the magnitude of an antitumor response.

E Hawrylko, G B Mackaness.   

Abstract

Mesh：

Substances：

Year:  1973        PMID： 4587143     DOI： 10.1093/jnci/51.5.1683

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

Review 2.  Modulation of antitumor immunity--immunobiologic approaches.

Authors:  R J North; E S Dye; C D Mills; J P Chandler
Journal:  Springer Semin Immunopathol       Date:  1982

3.  Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants.

Authors:  D Juy; L Chedid
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

4.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.